NASDAQ:LXRX

Lexicon Pharmaceuticals Stock Forecast, Price & News

$4.74
-0.05 (-1.04 %)
(As of 06/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.68
$4.87
50-Day Range
$4.12
$5.43
52-Week Range
$1.03
$9.65
Volume475,065 shs
Average Volume3.00 million shs
Market Capitalization$684.40 million
P/E RatioN/A
Dividend YieldN/A
Beta1.47
30 days | 90 days | 365 days | Advanced Chart
Receive LXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Lexicon Pharmaceuticals logo

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.47 out of 5 stars

Medical Sector

640th out of 2,102 stocks

Pharmaceutical Preparations Industry

310th out of 832 stocks

Analyst Opinion: 3.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions

Is Lexicon Pharmaceuticals a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Lexicon Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LXRX, but not buy additional shares or sell existing shares.
View analyst ratings for Lexicon Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Lexicon Pharmaceuticals?

Wall Street analysts have given Lexicon Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lexicon Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Lexicon Pharmaceuticals' next earnings date?

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Lexicon Pharmaceuticals
.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) issued its quarterly earnings data on Thursday, May, 6th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.02. The biopharmaceutical company had revenue of $0.03 million for the quarter, compared to analyst estimates of $3.35 million. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 13.04% and a negative net margin of 80.64%.
View Lexicon Pharmaceuticals' earnings history
.

How has Lexicon Pharmaceuticals' stock been impacted by COVID-19?

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LXRX shares have increased by 108.8% and is now trading at $4.74.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for LXRX?

6 analysts have issued 1 year price objectives for Lexicon Pharmaceuticals' stock. Their forecasts range from $6.00 to $13.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $9.40 in the next year. This suggests a possible upside of 98.3% from the stock's current price.
View analysts' price targets for Lexicon Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Lexicon Pharmaceuticals' key executives?

Lexicon Pharmaceuticals' management team includes the following people:
  • Mr. Lonnel Coats, Pres, CEO & Director (Age 56, Pay $1.15M)
  • Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 56, Pay $655.18k)
  • Mr. Brian T. Crum, VP, Gen. Counsel & Sec. (Age 48, Pay $536.92k)
  • Dr. Alan J. Main, Exec. VP of Innovation & Chemical Sciences (Age 67, Pay $560.17k)
  • Dr. Robert J. Lefkowitz, Consultant & Independent Director (Age 77, Pay $50k)
  • Mr. James F. Tessmer, VP of Fin. & Accounting (Age 61)
  • Chas Schultz, Exec. Director of Corp. Communications & Patient Advocacy

What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?

9 employees have rated Lexicon Pharmaceuticals CEO Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among Lexicon Pharmaceuticals' employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Lexicon Pharmaceuticals' key competitors?

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (5.81%), BlackRock Inc. (2.70%), D. E. Shaw & Co. Inc. (2.08%), Pinnacle Associates Ltd. (1.50%), Geode Capital Management LLC (0.75%) and Nomura Holdings Inc. (0.64%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats and Sam L Barker.
View institutional ownership trends for Lexicon Pharmaceuticals
.

Which institutional investors are selling Lexicon Pharmaceuticals stock?

LXRX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Morgan Stanley, Acadian Asset Management LLC, Millennium Management LLC, Renaissance Technologies LLC, Strs Ohio, Price T Rowe Associates Inc. MD, and Cubist Systematic Strategies LLC.
View insider buying and selling activity for Lexicon Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Lexicon Pharmaceuticals stock?

LXRX stock was acquired by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., BlackRock Inc., Nomura Holdings Inc., Boothe Investment Group Inc., Eversept Partners LP, Pinnacle Associates Ltd., Geode Capital Management LLC, and Nuveen Asset Management LLC. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, and Sam L Barker.
View insider buying and selling activity for Lexicon Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $4.74.

How much money does Lexicon Pharmaceuticals make?

Lexicon Pharmaceuticals has a market capitalization of $684.40 million and generates $24 million in revenue each year. The biopharmaceutical company earns $-58,570,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Lexicon Pharmaceuticals have?

Lexicon Pharmaceuticals employs 78 workers across the globe.

What is Lexicon Pharmaceuticals' official website?

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

Where are Lexicon Pharmaceuticals' headquarters?

Lexicon Pharmaceuticals is headquartered at 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000 or via email at [email protected]


This page was last updated on 6/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.